SCHEMBL4724633

SCHEMBL4724633

CC(C)(C)[Si](C)(C)O/N=C1\CCc2cc(Br)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 2/20 0.36
SRD5A2 P31213 1/20 0.36
CYP19A1 P11511 6/20 0.36
CYP11B1 P15538 6/20 0.36
CYP11B2 P19099 6/20 0.36
PARP10 Q53GL7 1/20 0.34
PARP11 Q9NR21 1/20 0.34
TYMS P04818 1/20 0.33
HTT P42858 1/20 0.32
MAPT P10636 3/20 0.32
NPC1 O15118 2/20 0.32
NFKB1 P19838 2/20 0.32
RAB9A P51151 2/20 0.32
NFKB2 Q00653 2/20 0.32
RELA Q04206 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
APLNR P35414 2/20 0.30
PTAFR P25105 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4791976 1.00 SRD5A1 (0.36) SRD5A1SRD5A2CYP19A1CYP11B1CYP11B2
SCHEMBL4722731 1.00 SRD5A1 (0.36) SRD5A1SRD5A2CYP19A1CYP11B1CYP11B2
SCHEMBL4761270 0.83 CASP1 (0.41) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL5621592 0.83 CASP1 (0.41) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL9075051 0.82 HTT (0.31) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL9075055 0.82 HTT (0.31) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL9075058 0.82 HTT (0.31) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL4487934 0.80 MAPT (0.30) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL13790132 0.80 HTT (0.33) HTTMAPTNPC1NFKB1RAB9A
SCHEMBL4497035 0.80 MAPT (0.30) HTTMAPTNPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934228-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2008-06-25 EP disclosed
WO-2007027855-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-03-08 WO disclosed
WO-2007027855-A2 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-03-08 WO disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof ARRAY BIOPHARMA INC. 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049603-A1 Raf inhibitor compounds and methods of use thereof BRAF, RAF1, ARAF SRD5A1 1761/4885SRD5A2 2553/4885CYP19A1 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.